文献速递糖尿病

IA-2A阳性增加1型糖尿病各已确立分期内及跨分期的进展风险

IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes.
PubMed 文献 · Diabetologia · 2025-02-28

基于TrialNet Pathway to Prevention研究中4577例自身抗体阳性及192例自身抗体阴性的1型糖尿病亲属纵向数据,采用Cox回归比较不同抗体谱和疾病分期的临床糖尿病累积发病率。结果显示IA-2A阳性者在单抗体阳性、1期和2期分类中5年进展风险分别增加5.3倍、2.2倍和1.3倍。作者认为应考虑将IA-2A阳性状态纳入自身抗体阳性个体的监测策略。

要点

  • IA-2A阳性者在单抗体阳性、1期和2期分类中5年进展风险分别增加5.3倍、2.2倍和1.3倍。
  • 单IA-2A阳性者中风险最高亚组包括儿童(HR 14.2)、IA-2A滴度高于中位数者(HR 3.5)、高遗传风险评分者(HR 1.4)和HLA DR4阳性者(HR 3.7)。
  • 作者认为应考虑将IA-2A阳性状态纳入自身抗体阳性个体的监测策略。

核心结论

  • IA-2A阳性在整个1型糖尿病自然史中持续与进展风险增加相关。
  • 单IA-2A阳性者疾病进展风险高于符合1期标准但IA-2A阴性者。
  • 作者认为应考虑将IA-2A阳性状态纳入自身抗体阳性个体的监测策略。

研究设计与样本

  • 分析TrialNet Pathway to Prevention研究中纵向随访的1型糖尿病个体亲属的遗传、自身抗体和代谢数据。
  • 纳入成人及儿童自身抗体阴性亲属192例和自身抗体阳性亲属4577例。
  • 采用Cox回归比较不同自身抗体谱和疾病分期的临床糖尿病累积发病率。

主要发现

  • 与IA-2A阴性者相比,IA-2A阳性者在单抗体阳性分类中5年风险增加5.3倍,在1期分类中增加2.2倍,在2期分类中增加1.3倍。
  • 单IA-2A阳性者较自身抗体阴性者、其他单抗体阳性者及IA-2A阴性1期个体代谢功能障碍和糖尿病进展增加。
  • 单IA-2A阳性者中,儿童HR 14.2(95%CI 1.9,103.1),p=0.009。
  • 单IA-2A阳性者中,IA-2A滴度高于中位数者HR 3.5(95%CI 1.9,6.6),p<0.001;高遗传风险评分者HR 1.4(95%CI 1.2,1.6),p<0.001;HLA DR4阳性者HR 3.7(95%CI 1.6,8.3),p=0.002。
  • 在所有自身抗体阳性个体中,血糖正常的IA-2A阳性者与血糖异常的IA-2A阴性者进展风险相似。

临床怎么用

  • 作者认为应考虑将IA-2A阳性状态纳入自身抗体阳性个体的监测策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Accurate understanding of type 1 diabetes risk is critical for optimisation of counselling, monitoring and interventions, yet even within established staging classifications, individual time to clinical disease varies. Previous work has associated IA-2A positivity with increased type 1 diabetes progression but a comprehensive assessment of the impact of screening for IA-2A positivity across the natural history of autoantibody positivity has not been performed. We asked whether IA-2A would consistently be associated with higher risk of progression within and across established stages of type 1 diabetes in a large natural history study. METHODS: Genetic, autoantibody and metabolic data from adult and paediatric autoantibody-negative (n=192) and autoantibody-positive (n=4577) relatives of individuals with type 1 diabetes followed longitudinally in the Type 1 Diabetes TrialNet Pathway to Prevention Study were analysed. Cox regression was used to compare cumulative incidences of clinical diabetes by autoantibody profiles and disease stages. RESULTS: Compared with IA-2A- individuals, IA-2A+ individuals had higher genetic risk scores and clinical progression risk within single-autoantibody-positive (5.3-fold increased 5 year risk), stage 1 (2.2-fold increased 5 year risk) and stage 2 (1.3-fold increased 5 year risk) type 1 diabetes categories. Individuals with single-autoantibody positivity for IA-2A showed increased metabolic dysfunction and diabetes progression compared with people who were autoantibody negative, those positive for another single autoantibody, and IA-2A- stage 1 individuals. Individuals at highest risk within the single-IA-2A+ category included children (HR 14.2 [95% CI 1.9, 103.1], p=0.009), individuals with IA-2A titres above the median (HR 3.5 [95% CI 1.9, 6.6], p<0.001), individuals with high genetic risk scores (HR 1.4 [95% CI 1.2,1.6], p<0.001) and individuals with HLA DR4-positive status (HR 3.7 [95% CI 1.6, 8.3], p=0.002). When considering all autoantibody-positive individuals, progression risk was similar for euglycaemic IA-2A+ individuals and dysglycaemic IA-2A- individuals. CONCLUSIONS/INTERPRETATION: IA-2A positivity is consistently associated with increased progression risk throughout the natural history of type 1 diabetes development. Individuals with single-autoantibody positivity for IA-2A have a greater risk of disease progression than those who meet stage 1 criteria but who are IA-2A-. Approaches to incorporate IA-2A+ status into monitoring strategies for autoantibody-positive individuals should be considered.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Sims EK, Cuthbertson D, Ferrat LA, et al. IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes. Diabetologia. 2025. PMID: 40016443. doi:10.1007/s00125-025-06382-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。